Yongxian Hu

27PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Aug 10, 2026
Correction: CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

|Jul 22, 2026
The Gut Microbiome Drives Endogenous T Cell Activation Following CAR-T Cell Therapy.

|Jul 08, 2026
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies.

|Jul 03, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

|May 15, 2026
CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study.

|May 14, 2026
Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up.

Pageof 5

Frequent Collaborators

19 joint publications

He Huang

4 joint publications

Alex Hongsheng Chang

3 joint publications

Dongrui Wang

3 joint publications

Houli Zhao